Evolución y salud: evolución experimental y epidemiología
EVOSALUD
![Foto de Evolución y salud: evolución experimental y epidemiología](/img/grupo.png)
![Foto de GlaxoSmithKline (Spain)](/img/noimage_org.png)
GlaxoSmithKline (Spain)
Madrid, EspañaPublicaciones en colaboración con investigadores/as de GlaxoSmithKline (Spain) (4)
2002
-
Activities of six different quinolones against clinical respiratory isolates of streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain
Antimicrobial Agents and Chemotherapy, Vol. 46, Núm. 8, pp. 2665-2667
-
Activity of six quinolones against 226 recent clinical isolates of Streptococcus pyogenes with reduced susceptibility to ciprofloxacin [3]
Journal of Antimicrobial Chemotherapy
-
Susceptibility patterns of bacteria causing community-acquired respiratory infections in Spain: The SAUCE project
Journal of Antimicrobial Chemotherapy, Vol. 50, Núm. SUPPL. 2, pp. 21-26
2001
-
Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999
Antimicrobial Agents and Chemotherapy, Vol. 45, Núm. 11, pp. 3226-3228